肝动脉化疗栓塞治疗原发性肝癌25例临床分析

Effect of TACE for Primary Liver Cancer

目的:探讨经肝动脉化疗栓塞术治疗原发性肝癌的方法和疗效。方法:对(2007～2008)年我院就诊的25例行肝动脉化疗栓塞疗的原发性肝癌患者进行了随访和回顾性分析。结果:①本组病例TACE治疗后肝区疼痛、腹胀减轻,腹水、黄疸逐渐消退,精神食欲改善,体重增加19例(76.0%)。③TACE治疗前肿瘤直径(8.36±2.51)cm,治疗后直径(3.02±0.88)cm,血供消失或减少,肿瘸染色越越淡22例(88.0%)。③TACE治疗前肿瘤AFP为(169.92±462.50)ng/1,治疗后(194.07±25.87)ng/1。④TACE治疗后(1、2、3)年生存率别为88.0%(22/25)、68.0%(17/25)和40.0%(10/25)。⑤TACE术后76.0%(19/25)伴有不同程度腹痛、腹胀、恶心或呕吐、纳差等消化道应:64.0%(16/25)术后第二天出现发热,一般在38.5℃以下:8.0%(2/25)有转氨酶轻至中度升高或出现轻度黄疽,外周血白细胞下降,偶尔上消化道出血。上述不良反应均经保肝和对症治疗后恢复。结论:TACE是治疗中、晚期原发性肝癌的有效手段,可使症状明显改善,瘤缩小,生存率提高。

Objective： To evaluate the method and effect of the treatment of TACE for primary liver cancer. Methods： 25 cases of primary liver cancer patients underwent hepatic artery chemoembolization in our hospital from 2007 to 2008 were followed up and analyzed retrospectively. Results： （1）Liver pain and abdominal distension of the patients reduced after TACE treatment, jaundice gradually subsided, spirit and appetite improved, weight gain in 19 cases （76.0%）. （2）tumor diameter was （8.36 ± 2.51） cm before TACE treatment, diameter （3.02 ±0.88） cm after treatment, blood supply disappeared or reduced, tumors staining grew weaker and weaker in 22 cases （88,0%）. （3）tumor AFP was （169.92± 462.50） ng/ l in pretreatment of TACE, （194.07 ± 25.87） ng/l after treatment. （4）（1,2,3） year survival rates were respectively 88.0% （22/25）, 68.0% （17/25） and 40.0% （10/25） after TACE treatment. （5）after TACE, 76.0% （19/25） with varying degrees of abdominal pain, abdominal distention, nausea or vomiting, anorexia and other gastrointestinal reaction; 64.0% （16/25） fever after the second day, usually below 38.5 ℃; 8.0% （2 / 25） with mild to moderately elevated transaminases or mild jaundice, decreased white blood cells, and occasionally with upper gastrointestinal bleeding. The adverse reactions above by symptomatic treatment of liver protection recovered. Conclusion： TACE is an effective treatment means of mid and advanced primary liver cancer, will enable symptoms significantly improve, tumor shrinkage, survival rates increase.rimary liver cancer, will enable symptoms significantly improve, tumor shrinkage, survival rates increase.